Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
Clinical trial NCT06907511 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06907511
- Sponsor
- Sanofi
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-17
- Primary completion
- 2026-12-01
- Enrollment
- 720
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.